Stockholm, Sweden, August 18, 2026
AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly and Company, completing the initial transaction under their collaboration and licensing agreement for Alzstatin, including the investigational Alzheimer’s disease candidate ACD680. The agreement, originally signed on June 9, 2026, gives Lilly global rights to Alzstatin and responsibility for the continued clinical development and commercialization of ACD680. The completion follows satisfaction of customary closing conditions, including approval under Swedish regulations governing the screening of foreign direct investments and acquisitions. For AlzeCure, the completed transaction strengthens its financial position without dilution for shareholders while transferring responsibility for the global advancement of ACD680 to Lilly. The collaboration also includes development and commercial milestone payments and mid-single-digit royalties on future product sales, with the total agreement value potentially exceeding $1 billion, excluding royalties.
Alzstatin Program Advances Alzheimer’s Drug Development
The transaction centers on ACD680, a small-molecule gamma-secretase modulator being developed through AlzeCure’s Alzstatin research platform. The candidate is designed to influence the production of amyloid-beta proteins, with a specific focus on reducing the formation of Aβ42, a form of amyloid-beta associated with the development of amyloid plaques in Alzheimer’s disease. At the same time, ACD680 is designed to increase production of shorter Aβ37 and Aβ38 peptides, which are considered non-toxic and may have the potential to reduce aggregation of Aβ42. This mechanism represents the scientific foundation of the Alzstatin approach and provides the basis for Lilly’s decision to assume global development rights. With the transaction now completed, Lilly will lead the next stages of clinical development and potential commercialization of the program. The agreement therefore marks a significant transition for ACD680, moving the program into a global pharmaceutical development structure while AlzeCure retains broader research activities in CNS diseases.
Lilly Deal Strengthens AlzeCure’s CNS Pipeline Strategy
The $10 million upfront payment provides AlzeCure with additional financial resources as the company continues developing its broader pipeline in Alzheimer’s disease and pain. Although Lilly has assumed global rights to Alzstatin, AlzeCure has stated that it will remain active in Alzheimer’s research through its Alzstatin and NeuroRestore platforms. The company is also increasing its focus on its pain portfolio, particularly programs involving TrkA-NAM and ACD440. This diversification is strategically important because the completed Lilly transaction reduces the financial burden associated with independently advancing ACD680 while allowing AlzeCure to continue investing in additional CNS drug candidates. The company’s broader research strategy is built around three platforms: NeuroRestore, Alzstatin and Painless, targeting severe neurological conditions where treatment options remain limited. The Lilly agreement also demonstrates the potential commercial value of AlzeCure’s small-molecule CNS research and provides a pathway for its Alzheimer’s technology to progress under a major pharmaceutical partner..
Advertisement
AlzeCure Completes Initial Transaction With Lilly
Completion of the transaction represents a key corporate and development milestone for AlzeCure Pharma, with the full upfront payment now received and all conditions for the initial transaction satisfied. Importantly, the payment does not dilute existing shareholders, while future milestone payments and royalties could provide additional financial value if ACD680 advances successfully through development and commercialization. For the Alzheimer’s disease field, the collaboration places a novel gamma-secretase modulation approach under Lilly’s global development capabilities, while AlzeCure can redirect greater resources toward its remaining CNS programs. The company’s continued presence in both Alzheimer’s disease and pain gives it a diversified development strategy rather than making its future dependent on a single asset. The completion of the transaction therefore strengthens AlzeCure’s financial position and establishes a new development pathway for ACD680 and the Alzstatin platform as the companies move forward with their respective responsibilities.
Source:AlzeCure Pharma press relese
